跳至主要内容
临床试验/NCT05529459
NCT05529459招募中不适用

ASSIST Trial Anatomic Versus Physiologic Guidance for Complete Revascularization With Drug Eluting Stent Implantation in Patients With Coronary Artery Disease

Seung-Whan Lee, M.D., Ph.D.17 个研究点 分布在 1 个国家目标入组 2,400 人开始时间: 2023年3月13日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
2,400
试验地点
17
主要终点
Number of Participants with unplanned repeat revascularization

研究概览

简要总结

This study is to compare clinical outcomes between quantitative coronary angiography-guided anatomic complete revascularization and fractional flow reserve-guided physiologic complete revascularization in patients with significant coronary artery disease undergoing percutaneous coronary intervention with drug eluting stent

详细描述

This is a prospective, multicenter center, open-label, randomized trial to compare QCA-guided versus FFR-guided CR strategies in patients with significant CAD who are undergoing PCI with DES. Patients with symptoms or evidence of myocardial ischemia are eligible for enrollment if there have stenotic lesions with a diameter stenosis of 50%-90% in major epicardial coronary arteries ≥ 2.25 mm in diameter by visual estimation, and CR is expected to be achievable by PCI. The detailed information for inclusion and exclusion criteria is described below in the session 4. Patients meeting inclusion criteria without any exclusion criteria will be randomized to either QCA-guided CR or FFR-guided CR group. In the QCA-guided CR group, PCI will be performed if there are lesions with diameter stenosis ≥ 50% by QCA during the index procedure (and, if necessary, planned staged procedure). In the FFR-guided CR group, FFR is measured for the target coronary lesions, and then PCI will be performed for the lesions with FFR ≤0.80. Post-PCI FFR measurement is strongly recommended. However, additional procedures are not recommended based on post-PCI FFR value because there is no consensus of the optimal cut-off value to define physiologic CR. In both QCA-guided and FFR-guided PCI groups, imaging guidance during PCI is left at the discretion of the operator. However, routine high pressure post-dilation with noncompliant balloons is recommended to achieve optimal stent expansion with minimal residual stenosis (diameter stenosis < 10% on visual estimation). Patients will be followed clinically at 1, 6, 12 months, and then upto 5 years after the index procedure

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
Single (Participant)

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men or women between the ages of 19and older
  • Typical chest pain or objective evidence of myocardial ischemia suitable for PCI Significant lesions with a diameter stenosis of 50-90% in major epicardial coronary arteries ≥ 2.25 mm in diameter by visual estimation.
  • The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

排除标准

  • Coronary lesions resulting in the expected inability to perform FFR (ex, severe tortuosity or extreme angulation of the vessels)
  • Chronic total occlusion
  • Failed PCI of severe stenotic (diameter stenosis > 90%) or ACS culprit lesions
  • Previous PCI within 6 months before the index procedure
  • Previous coronary artery bypass graft surgery
  • Cardiogenic shock or hemodynamic instability
  • Left ventricular dysfunction (ejection fraction < 35%)
  • Life expectancy < 1 years for any non-cardiac or cardiac causes
  • Any surgery requiring general anesthesia or discontinuation of aspirin and/or an ADP antagonist is planned within 12 months after the procedure
  • A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer
  • Patient's pregnant or breast-feeding or child-bearing potential.
  • A known intolerance to antiplatelet agents (aspirin, clopidogrel, prasugrel or ticagrelor)
  • Hypersensitivity or contraindication to DES material and its degradants and cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be adequately pre-medicated
  • Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the investigator, would preclude safe completion of the study
  • Unwillingness or inability to comply with the procedures described in this protocol

结局指标

主要结局

Number of Participants with unplanned repeat revascularization

时间窗: 12month

Unplanned repeat revascularization is defined as revascularization of any diseased coronary arteries ≥ 2.0 mm in diameter by QCA due to recurred angina with at least one of the following: (1) positive non-invasive test, (2) positive invasive physiologic test, or (3) presence of diameter stenosis ≥50% by QCA.

Number of Participants with death

时间窗: 12month

Major adverse cardiac events are defined as all-cause death

Number of Participants with MI

时间窗: 12month

Non-fatal myocardial infarction includes both spontaneous MI and periprocedural MI.

次要结局

  • cost-effectiveness(5years)
  • Number of Participants with bleeding(5years)
  • Number of Participants with unplanned repeat revascularization(5years)
  • Number of Participants with death(5years)
  • Number of Participants with MI(5years)
  • Self-rated health on a vertical visual analogue scale by EQ5D(5years)
  • Number of Participants with rehospitalization(5years)

研究者

发起方
Seung-Whan Lee, M.D., Ph.D.
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Seung-Whan Lee, M.D., Ph.D.

Principal investigator

Asan Medical Center

研究点 (17)

Loading locations...

相似试验